Vivacitas Oncology Presents for the Second Year in a row at the 2022 SAPA Conference

Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October 1st, 2022 at the 2022 Sino-American Pharmaceutical Professional Association (SAPA) Conference.

The SAPA Annual Conference is a tremendous platform for participants to share knowledge and viewpoints on important issues and current trends in academic research, pharma, and the biotech industry. The event features presentations and panel discussions by distinguished speakers and panelists from academia and the industry to provide opportunities for scientific exchange, public health education, networking, investments, career development, and business collaborations.

The 2022 Annual Conference will take place in Somerset New Jersey on Friday, September 30th to Saturday, October 1st, 2022.  There will be roughly 500 attendees in person and 300 online participants. 

Scott VanderMeer, Interim CEO, CFO, Director & Co-Founder of Vivacitas Oncology will give a 20-minute presentation and hold a Q&A at the event. “It is great to be back at SAPA for the second year in a row to connect with world-class professionals and to speak with investors about our progress over the last year will be good exposure for the company”, he stated.

ABOUT SAPA

The Sino-American Pharmaceutical Professionals Association (SAPA) Conference was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the United States with eight chapters and more than 6,000 members.

For more information, please visit https://sapaweb.org/ac2022/.

ABOUT VIVACITAS ONCOLOGY, INC.

Vivacitas Oncology is a private clinical-stage biopharmaceutical company focused on tough-to-treat cancers.  It originated with the vision of Dr. Joseph Rubinfeld (co-founder of Amgen) and Infusion 51a, LP to transform select chemotherapies beyond their initial potency, toxicity, stability, and/or pharmacokinetics challenges and unlock maximum treatment and tolerability potential. Through an enduring spirit, Vivacitas and its Executive Team continue to apply clarity, tenacity, and vision in their fight against aggressive cancers and the pursuit of new treatment options for patients and families worldwide.

For further information please visit www.vivaoncology.com or email elise@vivaoncology.com.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org